Growth Opportunities in the Global Liquid Biopsy Market, 2018

Growth Opportunities in the Global Liquid Biopsy Market, 2018

Companies are Vying for a Higher Market Position in the Early Cancer Screening Market

RELEASE DATE
05-Oct-2018
REGION
North America
Research Code: K294-01-00-00-00
SKU: HC03094-NA-MT_22419

$4,950.00

Special Price $3,712.50 save 25 %

In stock
SKU
HC03094-NA-MT_22419

$4,950.00

$3,712.50 save 25 %

DownloadLink

Pay by invoice

ENQUIRE NOW

Description

Liquid biopsy (CTCs and ctDNAs) is slowly gaining momentum in clinical care given its advantages over the traditional tissue-based gold standard methods. Short-term applications in cancer care range from risk assessment to cancer recurrence monitoring. Despite the proven advantages, there is still a significant number of barriers to adoption such as high cost of next-generation sequencing (NGS), reimbursement scenario and the establishment of clinical utility of mutation and clinical evidence.

Liquid biopsy remains an interesting business opportunity for several investors and the quest for the most successful company continues. With GRAIL announcing over $1.3 billion in financing, the modality has also garnered interest from several pharma companies vying to capture their share of the market by co-developing drugs and diagnostic products. CTCs and ctDNAs have extended applications across oncology, NIPT (non-invasive prenatal testing), transplant diagnostics and infectious diseases. This report provides a strategic insight into liquid biopsy test makers relating to the challenges they will encounter and lists some of the winning strategies to gain reimbursement and market access. It also highlights growth opportunities where companies can gain the first-mover advantage, and provides a guidance for investment bankers on the most successful and unique disruptive technology.

It is important to identify winning strategies in order to be successful. Given the tricky nature of this market, establishing clinical utility and clinical evidence and getting the test into guidelines are some of the key pathways for success. This report discusses regional challenges, regulatory barriers in the UK, China and the US. Key drivers would include the following: Identifying the area of unmet need; aiming for incorporating the test within guidelines and screening programs; overcoming regulatory and reimbursement barriers; and innovating to draw maximum capital from investors.

Broadly three types of companies form the competitive landscape in this market - liquid biopsy kit providers, liquid biopsy instrument providers. Most activity is sensed within “liquid biopsy as a service model”.

Currently, there are no clear guidelines that provide a definitive regulatory/ reimbursement roadmap in emerging countries such as India where the concept is still in its nascent stages.

Top market trends include:
•     Increasing interest from pharma companies forging partnerships with diagnostic test developers to advance their drug discovery and development activities.
•     Companies are leaning towards biomarkers that are listed in the NCCN guidelines as a low-risk approach and which offer more guaranteed reimbursement.
•     Biomarker tests are focusing on multi-gene or multi-cancer testing rather than a single gene approach.
•     Companies are pushing the boundaries beyond oncology testing.

Table of Contents

Purpose of this Experiential Study

5 Step Process to Transformational Growth

Scope and Segmentation

Market Highlights

Strategic Imperatives for Suppliers and Laboratories

Growth Themes for the Liquid Biopsy Market

Top 3 Predictions

What is Liquid Biopsy?

Overview of Liquid Biopsy Techniques and Biomarkers

Liquid Biopsy—Where are the Growth Opportunities?

Tapping into Oncology-specific Opportunities

Deeper Look Into Biopsies

Key Stakeholders (Full Adoption of Liquid Biopsy)

Clinical Trials in Liquid Biopsy

Market Landscape—Pharmaceutical Investments

Market Drivers

Market Restraints

Commercialized Tests (US)

Impact of NCD on Liquid Biopsy Testing

Notable Market Activities

Market Landscape—Investments

Overall Competitive Landscape—Types of Companies

Overview of Competitive Landscape—Service Providers

Top 3 Trends and Vendor Strategies

Key Focus Areas of Liquid Biopsy Companies

Liquid Biopsy Service Provider—Competitor Analysis Snapshot

Investments and Technology—By Company

Investments—By Technology

Biomarker and Technology Choice Analysis

Competitor Matrix—Product Type

Predictions on Adoption of Liquid Biopsy Across Geographies

Analysis—US

Analysis—Europe/UK

Analysis—China

Analysis—India

Growth Opportunities

Growth Opportunity 1—Tool to Predict Response to Therapy

Growth Opportunity 2—Prognosis and Early Detection for Cancer

Growth Opportunity 3—Moving Beyond Routine Cancers

Growth Opportunity 4—Technology Advancements

2018 Liquid Biopsy Market Participant Strategies

Winning Strategies—Recommended Growth Strategies

Importance of Clinical Validation and Clinical Utility and Path to Reimbursement

GRAIL—Strong Clinical Trial Strategy and Technology Superiority Using AI/ML

Guardant Health—Established Presence in Recurrence Monitoring

Biocept

Natera—Building on the NIPT Expertise

Path to Reimbursement/Coverage

Key Conclusions and Future Outlook

Acronyms

Legal Disclaimer

List of Companies Mentioned in the Report

List of Exhibits

List of Figures
  • 1. Liquid Biopsy Market: Number of Biopsies, US, 2017-2021
  • 2. Liquid Biopsy Market: Key Market Drivers, Global, 2018–2022
  • 3. Liquid Biopsy Market: Key Market Restraints, Global, 2018–2022
  • 4. Liquid Biopsy Market: Assessment of Notable Activities, US, 2015-2018
  • 5. Liquid Biopsy Market: Competitor Matrix by Product Type, 2018
  • 6. Liquid Biopsy Market: Liquid Biopsy Market Participant Strategies, US, 2018
  • 7. Total Liquid Biopsy Market: Key Conclusions and Future Outlook, US, 2018
  • 8.
  • 9. Total Mass Spectrometry Market: Key Market Drivers, Global, 2018-2024
List of Charts
  • 1. Liquid Biopsy Market: Areas of Application, Global, 2017
  • 2. Total Public and Private Investment in Liquid Biopsy Companies Competitive Set 2013–2018
  • 3. Liquid Biopsy: Investments by Technology, Global, 2018 (June)
  • 4. Liquid Biopsy Market: Biomarker and Technology Choice Analysis, Global, 2018 (June)
  • 5.
  • 6. Total Mass Spectrometer Market: Market Engineering Measurements, Global, 2017
Related Research
Liquid biopsy (CTCs and ctDNAs) is slowly gaining momentum in clinical care given its advantages over the traditional tissue-based gold standard methods. Short-term applications in cancer care range from risk assessment to cancer recurrence monitoring. Despite the proven advantages, there is still a significant number of barriers to adoption such as high cost of next-generation sequencing (NGS), reimbursement scenario and the establishment of clinical utility of mutation and clinical evidence. Liquid biopsy remains an interesting business opportunity for several investors and the quest for the most successful company continues. With GRAIL announcing over $1.3 billion in financing, the modality has also garnered interest from several pharma companies vying to capture their share of the market by co-developing drugs and diagnostic products. CTCs and ctDNAs have extended applications across oncology, NIPT (non-invasive prenatal testing), transplant diagnostics and infectious diseases. This report provides a strategic insight into liquid biopsy test makers relating to the challenges they will encounter and lists some of the winning strategies to gain reimbursement and market access. It also highlights growth opportunities where companies can gain the first-mover advantage, and provides a guidance for investment bankers on the most successful and unique disruptive technology. It is important to identify winning strategies in order to be successful. Given the tricky nature of this market, establishing clinical utility and clinical evidence and getting the test into guidelines are some of the key pathways for success. This report discusses regional challenges, regulatory barriers in the UK, China and the US. Key drivers would include the following: Identifying the area of unmet need; aiming for incorporating the test within guidelines and screening programs; overcoming regulatory and reimbursement barriers; and innovating to draw maximum capital from investors. Broadly
More Information
No Index No
Podcast No
Table of Contents | Executive Dashboard~ || Purpose of this Experiential Study~ || 5 Step Process to Transformational Growth~ || Scope and Segmentation~ || Market Highlights~ || Strategic Imperatives for Suppliers and Laboratories~ || Growth Themes for the Liquid Biopsy Market~ || Top 3 Predictions~ | Market Overview~ || What is Liquid Biopsy?~ || Overview of Liquid Biopsy Techniques and Biomarkers~ || Liquid Biopsy—Where are the Growth Opportunities?~ || Tapping into Oncology-specific Opportunities~ || Deeper Look Into Biopsies~ || Key Stakeholders (Full Adoption of Liquid Biopsy)~ || Clinical Trials in Liquid Biopsy~ || Market Landscape—Pharmaceutical Investments~ || Market Drivers~ || Market Restraints~ || Commercialized Tests (US)~ || Impact of NCD on Liquid Biopsy Testing~ || Notable Market Activities~ || Market Landscape—Investments~ | Competitor Landscape~ || Overall Competitive Landscape—Types of Companies~ || Overview of Competitive Landscape—Service Providers~ || Top 3 Trends and Vendor Strategies~ || Key Focus Areas of Liquid Biopsy Companies~ || Liquid Biopsy Service Provider—Competitor Analysis Snapshot~ || Investments and Technology—By Company~ || Investments—By Technology~ || Biomarker and Technology Choice Analysis~ || Competitor Matrix—Product Type~ | Regional Analysis~ || Predictions on Adoption of Liquid Biopsy Across Geographies~ || Analysis—US~ || Analysis—Europe/UK~ || Analysis—China~ || Analysis—India~ | Growth Strategy~ || Growth Opportunities~ || Growth Opportunity 1—Tool to Predict Response to Therapy~ || Growth Opportunity 2—Prognosis and Early Detection for Cancer~ || Growth Opportunity 3—Moving Beyond Routine Cancers~ || Growth Opportunity 4—Technology Advancements~ || 2018 Liquid Biopsy Market Participant Strategies~ || Winning Strategies—Recommended Growth Strategies~ || Importance of Clinical Validation and Clinical Utility and Path to Reimbursement~ || GRAIL—Strong Clinical Trial Strategy and Technology Superiority Using AI/ML~ || Guardant Health—Established Presence in Recurrence Monitoring~ || Biocept~ || Natera—Building on the NIPT Expertise~ || Path to Reimbursement/Coverage~ | Last Word~ || Key Conclusions and Future Outlook~ || Acronyms~ || Legal Disclaimer~ | Appendix (Capital Pricing and Installed Base)~ || List of Companies Mentioned in the Report~ || List of Exhibits~
List of Charts and Figures 1. Liquid Biopsy Market: Number of Biopsies, US, 2017-2021~ 2. Liquid Biopsy Market: Key Market Drivers, Global, 2018–2022~ 3. Liquid Biopsy Market: Key Market Restraints, Global, 2018–2022~ 4. Liquid Biopsy Market: Assessment of Notable Activities, US, 2015-2018~ 5. Liquid Biopsy Market: Competitor Matrix by Product Type, 2018~ 6. Liquid Biopsy Market: Liquid Biopsy Market Participant Strategies, US, 2018~ 7. Total Liquid Biopsy Market: Key Conclusions and Future Outlook, US, 2018~ 8. ~ 9. Total Mass Spectrometry Market: Key Market Drivers, Global, 2018-2024~| 1. Liquid Biopsy Market: Areas of Application, Global, 2017~ 2. Total Public and Private Investment in Liquid Biopsy Companies Competitive Set 2013–2018~ 3. Liquid Biopsy: Investments by Technology, Global, 2018 (June)~ 4. Liquid Biopsy Market: Biomarker and Technology Choice Analysis, Global, 2018 (June)~ 5. ~ 6. Total Mass Spectrometer Market: Market Engineering Measurements, Global, 2017~ 7.
Author Divyaa Ravishankar
Industries Healthcare
WIP Number K294-01-00-00-00
Is Prebook No
GPS Codes 9562-B1,9568-B1,9600-B1,9611-B1,9627-B1,9A43-B1,9A44-B1